<DOC>
	<DOCNO>NCT01350947</DOCNO>
	<brief_summary>The primary objective study : Response treatment evaluate accord revise International Working Group ( IWG ) categories natural history , hematologic improvement cytogenetic response1 ; 2 . The primary objective : To determine rate complete hematologic response hematologic improvement ( accord IWG 2006 criterion ) CMML patient treat 5-azacitidine .</brief_summary>
	<brief_title>A Study 5-Azacitidine ( VidazaÂ® ) Patients With Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description>In study , eligible patient confirm diagnosis CMML treat 5-azacitidine determine rate complete hematologic response , hematologic improvement , complete partial cytogenetic response , overall progression free survival . To develop biomarkers associate response gain insight mechanisms determine response , gene expression profiling , genome-wide SNP array analysis , microRNA analysis , DNA methylation analysis perform prior therapy define time point study . Phosphoproteomics profile may include analysis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Diagnosis CMML define WHO criteria 1 . Persistent peripheral blood monocytosis 1 x 109/L least 3 month 2 . No Philadelphia chromosome BCRABL fusion gene 3 . Less 20 % blast blood bone marrow 4 . Dysplasia one myeloid lineages* * In absence dysplasia one myeloid lineages , diagnosis CMML still make ) c ) meet AND acquire clonal chromosomal abnormality present bone marrow cell , monocytosis present 3months AND cause monocytosis rule . 2 . Age 18 year old . Both men woman member race ethnic group include . 3 . ECOG performance status &lt; 3 4 . Adequate organ function define : 1 . Total bilirubin &lt; 2.5 x upper limit normal ( ULN ) 2 . Direct bilirubin &lt; 2 x ULN 3 . Creatinine &lt; 2 mg/dL 4 . ALT AST &lt; 2.5 x ULN 5 . Ability understand willingness sign write informed consent document 6 . Willingness use adequate contraception duration study 1 . Progression acute myeloid leukemia ( define least 20 % blast blood bone marrow ) . In unlikely event progression acute leukemia demonstrate `` screening '' bone marrow biopsy , discretion investigator enroll patient adequate discussion finding alternative therapy . Enrollment patient must report HCI PI . 2 . Presence activate mutation platelet derive growth factor receptor alpha beta , would suggest likely benefit imatinib treatment ( mutation usually obvious karyotyping fluorescence situ hybridization study ) 3 . Known suspected hypersensitivity 5azacitidine mannitol 4 . Clinically significant heart disease ( New York Heart Association Class III IV ) serious intercurrent illness psychiatric illness/social situation would limit compliance study requirement 5 . Major surgery within 28 day registration ( exception : central venous line placement ) , lack full recovery prior major surgery 6 . Prior therapy hypomethylating agent 7 . Cytotoxic chemotherapy le 2 week prior start study medication ( exception : hydroxyurea and/or anagrelide ) 8 . Erythropoietin darbepoietin , GCSF , GMCSF , thalidomide lenalidomide less 2 week day 1 cycle 1 9 . Concomitant cytotoxic chemotherapy ( exception : hydroxyurea 1 week per cycle ) 10 . Concomitant therapy investigational agent 11 . Other active malignancy except basal cell carcinoma skin carcinoma situ cervix . 12 . Pregnancy breastfeeding ( possible risk fetus infant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>CMML</keyword>
</DOC>